Table 14Summary of ablative therapy study and patient characteristics: nonrandomized comparative studies

Study
N
Rating
Study DesignIntervention PeriodInterventionAge, Mean or Median
(Range)
ECOG ScoreCP
A%; B%; C%
BCLC
A%; B%
Previous LDT %
Chok et al. 200653
91
Poor
Retrospective cohort02/2001 - 03/2004TACE with cisplatin (1 mg/mL), lipiodol (volume ration 1:1), gelatin sponge mixed with gentamicin sulfate (40 mg) via superselective arteries repeated 8 to 12 weeksMedian: 66
(47–85)
NRA: 78;
B: 20;
C: 2
NRNR
02/2001 - 03/2004Percutaneous (45%), laparoscopic (2%) or open (53%) RFA with cool-tip electrodesMedian: 62
(42–77)
NRA: 76;
B: 22;
C: 2
NRNR

Abbreviations: BCLC = Barcelona Clinic Liver Center hepatocellular carcinoma stage; CP = Child-Pugh liver cirrhosis class; ECOG = Eastern Cooperative Oncology Group; LDT = liver-directed therapy; N = number of patients; NR = not reported; RFA = radiofrequency ablation.

From: Results

Cover of Local Therapies for Unresectable Primary Hepatocellular Carcinoma
Local Therapies for Unresectable Primary Hepatocellular Carcinoma [Internet].
Comparative Effectiveness Reviews, No. 114.
Belinson S, Yang Y, Chopra R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.